LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Kodu・Aktsiate loetelu・Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

Suletud

SektorTervishoid

3.49 -1.97

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.45

Max

3.61

Põhinäitajad
By Trading Economics
Sissetulek	9.6M -162M
Müük	-14M 5.2M
Kasumimarginaal	-3,135.324
Töötajad	800
EBITDA	6.4M -141M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+108.89% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	27. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	-300M 2.1B
Eelmine avamishind	5.46
Eelmine sulgemishind	3.49

Uudiste sentiment

By Acuity

50%

155 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

4.15 / 4.75 Toetus ja vastupanu

Recursion Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. veebr 2026, 16:32 UTC

Tulu

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

13. veebr 2026, 21:57 UTC

Tulu

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

13. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

13. veebr 2026, 21:20 UTC

Tulu

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

13. veebr 2026, 21:05 UTC

Omandamised, ülevõtmised, äriostud

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

13. veebr 2026, 20:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13. veebr 2026, 20:45 UTC

Market Talk

Dollar Pares Down Early Losses -- Market Talk

13. veebr 2026, 20:39 UTC

Market Talk

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

13. veebr 2026, 20:28 UTC

Market Talk

Oil Settles Week Lower -- Market Talk

13. veebr 2026, 19:51 UTC

Tulu

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13. veebr 2026, 19:32 UTC

Market Talk

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13. veebr 2026, 19:32 UTC

Market Talk

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13. veebr 2026, 19:29 UTC

Tulu

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

13. veebr 2026, 18:18 UTC

Omandamised, ülevõtmised, äriostud

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

13. veebr 2026, 17:52 UTC

Tulu

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

13. veebr 2026, 17:16 UTC

Tulu

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13. veebr 2026, 17:10 UTC

Omandamised, ülevõtmised, äriostud

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

13. veebr 2026, 16:59 UTC

Tulu

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

13. veebr 2026, 16:39 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

13. veebr 2026, 16:11 UTC

Tulu

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

13. veebr 2026, 16:07 UTC

Market Talk

Hungarian Forint Could Rise Further -- Market Talk

13. veebr 2026, 15:54 UTC

Tulu

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

13. veebr 2026, 15:26 UTC

Market Talk

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

13. veebr 2026, 15:01 UTC

Tulu

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

13. veebr 2026, 15:00 UTC

Tulu

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

13. veebr 2026, 14:50 UTC

Market Talk

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

13. veebr 2026, 14:44 UTC

Tulu

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

13. veebr 2026, 14:22 UTC

Market Talk

Tulu

Global Energy Roundup: Market Talk

13. veebr 2026, 14:21 UTC

Market Talk

Tulu

TC Energy's Broadly Anticipated Results Expected To Have Neutral Response -- Market Talk

13. veebr 2026, 14:13 UTC

Market Talk

U.S. Natural Gas Futures Move Lower -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Recursion Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

108.89% tõus

12 kuu keskmine prognoos

Keskmine 7.75 USD 108.89%

Kõrge 11 USD

Madal 5 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Recursion Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Recursion Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

4.15 / 4.75Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

155 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.